Abstract
The COVID-19 pandemic had widespread impacts on health care delivery. Concerns that COVID-19 would disrupt access to potentially lifesaving treatment for people with opioid use disorder (OUD) prompted abrupt federal policy changes in March 2020 to allow increased telehealth delivery of buprenorphine,1 a first-line OUD treatment that is known to prevent overdose death and can be prescribed in office-based settings.2,3 These changes included eliminating the required initial in-person visit before a patient could be transitioned to telehealth under the public health emergency exception of the Ryan Haight Online Pharmacy Consumer Protection Act.4 Additionally, updated guidance from the Drug Enforcement Administration (DEA) and Substance Abuse and Mental Health Services Administration (SAMHSA) allowed—for the first time—buprenorphine visits for new and existing patients to be delivered by telephone (ie, audio-only).5 Policy makers and health care leaders are currently debating whether to maintain or roll back policies that have increased flexibility in buprenorphine delivery.6 To inform these decisions, it is important to understand the potential relationship of buprenorphine treatment modality (video, telephone, or in-person) with treatment outcomes, as well as the characteristics of patients who are more or less likely to access different modalities.

This publication has 48 references indexed in Scilit: